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Comprehensive assessment of cellular responses to the RTS,S/AS01E vaccine is 
needed to understand potential correlates and ultimately mechanisms of protection 
against malaria disease. Cellular responses recognizing the RTS,S/AS01E-containing 
circumsporozoite protein (CSP) and Hepatitis B surface antigen (HBsAg) were assessed 
before and 1  month after primary vaccination by intracellular cytokine staining and 
16-color flow cytometry in 105 RTS,S/AS01-vaccinated and 74 rabies-vaccinated 
participants (controls) in a pediatric phase III trial in Africa. RTS,S/AS01E-vaccinated 
children had significantly higher frequencies of CSP- and HBsAg-specific CD4+ T cells 
producing IL-2, TNF-α, and CD40L and HBsAg-specific CD4+ T producing IFN-γ and 
IL-17 than baseline and the control group. Vaccine-induced responses were identified 
in both central and effector memory (EM) compartments. EM CD4+ T cells expressing 
IL-4 and IL-21 were detected recognizing both vaccine antigens. Consistently higher 
response rates to both antigens in RTS,S/AS01E-vaccinated than comparator-vacci-
nated children were observed. RTS,S/AS01E induced polyfunctional CSP- and HBsAg-
specific CD4+ T cells, with a greater degree of polyfunctionality in HBsAg responses. In 
conclusion, RTS,S/AS01E vaccine induces T cells of higher functional heterogeneity and 
polyfunctionality than previously characterized. Responses detected in memory CD4+ 
T  cell compartments may provide correlates of RTS,S/AS01-induced immunity and 
duration of protection in future correlates of immunity studies.
Keywords: malaria, Plasmodium falciparum, vaccine, cellular immune responses, T cells, intracellular cytokine 
staining, flow cytometry
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inTrODUcTiOn
A highly efficacious vaccine can substantially contribute to 
control and eventual elimination of malaria. This life-threatening 
disease caused an estimated 429,000 deaths in 2015 (1), mainly 
among sub-Saharan African children. In 2009–2014, the RTS,S/
AS01E malaria vaccine was evaluated in a pediatric Phase III trial 
in Africa (2–4). Vaccine efficacy (VE) against clinical malaria 
over 1 year post-immunization was moderate (56%) in children 
enrolled at age 5–17 months and low (31%) in infants enrolled at 
age 6–12 weeks. Importantly, the protective effects waned quickly 
over time. To better understand why the RTS,S/AS01E vaccine 
induced only partial and short-lived protection against malaria, a 
thorough examination of the immune responses elicited, includ-
ing different effector functions and memory phenotypes, using 
qualified or validated assays to ensure appropriate assay sensitiv-
ity and specificity to detect small frequencies of antigen-specific 
cells is needed.
RTS,S is a vaccine based on the circumsporozoite protein 
(CSP) of Plasmodium falciparum, targeting the sporozoite and 
liver stages of infection. This self-assembling virus-like particle 
consists of a recombinant protein containing part of CSP fused 
to the hepatitis B surface antigen (HBsAg) and it is coexpressed 
with HBsAg alone. In the Phase III trial, RTS,S was formulated 
with AS01E liposomal adjuvant containing monophosphoryl 
lipid A and QS21 and was designed to induce strong anti-CSP 
antibody and T helper (TH) 1 cell responses. Accordingly, in 
past clinical trials in endemic areas, RTS,S consistently induced 
high anti-CSP IgG titers (5–11) and moderate TH1 CD4+ T cell 
responses (5–10). IgG titers have been recently shown to cor-
relate with vaccine-induced protection in secondary analysis 
of Phase III trial data (12, 13). However, IgG responses do not 
explain why RTS,S/AS01E VE is moderate or short-lived.
Regarding the cellular responses, CD4+ T  cells expressing 
IL-2, TNF-α, and IFN-γ (and CD40L in naïve adults) have been 
detected by intracellular cytokine staining (ICS) or ELISpot 
(5–11, 14, 15) upon vaccination. In vaccinated naïve adults 
challenged with P. falciparum-infected mosquitoes, CSP-specific 
CD4+ T cells and IFN-γ measured by ELISPot were associated 
with protection (11, 14, 15). One study evaluating RTS,S/AS02D 
in African children less than 1 year old did not find any associa-
tion with protection (5), whereas in another one with RTS,S/
AS01E in children 5–17  months old observed CSP-specific 
TNF-α+ CD4+ T cell responses to be associated with a reduced 
risk of clinical malaria independently of anti-CSP IgG titers 
(8). Polyfunctional analysis of the ICS data of the later study 
showed that IFN-γ-IL-2−TNF-α+ CD4+ T  cells independently 
predicted reduced risk of clinical malaria, although the response 
was also detected in control vaccinees, and found a synergistic 
interaction with anti-CSP IgG titers (9). CD8+ T cell responses 
were only detected in humans in two studies, one in infants in 
whom the responses were not correlated with protection and 
the other in naïve adults (5, 14). Interestingly, NK  cells were 
found to be the main producers of IFN-γ in one field trial, but 
its association with protection was not assessed (10). Overall, no 
clear cellular correlates of protection have been demonstrated 
in African trials although only a limited number of assays 
restricted to a few immune variables have been studied. There 
has been no assessment of other cell effector functions, such as 
TH2 or follicular helper T  cells (TFH), or memory phenotypes 
that may be induced by RTS,S/AS01E and could be correlated 
with antibody responses and involved in vaccine-induced 
protection. Interestingly, in the Phase III trial, we detected TH1 
responses in supernatants of CSP-stimulated cells associated 
with protection in RTS,S/AS01E vaccinees, whereas a TH2 
cytokine, IL-5, was associated with increased risk for malaria 
(16). To our knowledge, TH2 responses had only been examined 
in one previous study in humans, where IL-4 was found elevated 
in culture supernatants from RTS,S/AS02D-vaccinated infants 
(5). Lastly, memory T cell subsets have only been examined in 
a study with malaria-naïve adults who underwent a challenge 
with P. falciparum-infected mosquitoes after RTS,S vaccination. 
In that study, central memory T (TCM) cells and effector/effector 
memory T  cells from RTS,S-vaccinated adults produced IL-2 
after ex vivo CSP stimulation and frequencies were higher in 
protected vs. non-protected subjects (15).
Assessing the memory phenotype, the polyfunctionality 
degree and other relevant functions besides TH1 responses, such 
as TH2, TH17, cytotoxic, or immunoregulatory responses, may be 
key to identify functionally complex responses to RTS,S/AS01E 
and unravel its mode of action. In fact, complexity of the immune 
response to malaria and the partial and short-lived protection 
induced by RTS,S/AS01E stresses the need to expand the breadth 
of immunological profiling to TH2- and regulatory-type markers. 
This may be particularly relevant in infants in African settings, as 
they are exposed to prenatal and environmental factors that may 
modulate immune response to vaccines.
The aim of this study was to analyze RTS,S/AS01E cel-
lular immunogenicity after primary vaccination using two 
qualified 16-color multiparametric ICS assays that allow the 
assessment of memory cell subsets and regulatory, cytotoxic, 
TH1, TH2, TH17, TFH effector functions, most of them never 
assessed before, and to identify and establish a baseline of cell 
phenotypes and functional responses to be evaluated in stud-
ies of immune correlates of protection elicited by the vaccine. 
To this end, we analyzed the CSP- and HBsAg-specific cells 
ex vivo using previously cryopreserved peripheral blood mono-
nuclear cells (PBMC) isolated from a subset of children aged 
5–17  months at enrollment from Tanzania and Mozambique 
and following receipt of either the RTS,S/AS01E vaccine or a 
comparator rabies vaccine.
MaTerials anD MeThODs
study Population and study Design
We performed a study on a subset of 179 children aged 5–17 months 
from the RTS,S/AS01E Phase III trial (ClinicalTrials.gov 
NCT00866619), described elsewhere (4): 105 children received 
RTS,S/AS01E and 74 children received the rabies vaccine as a 
comparator at study months zero (M0), one, and two. PBMC were 
collected at M0 before vaccination and approximately 30  days 
after the third vaccination dose (M3). RTS,S/AS01E-vaccinated 
and rabies-vaccinated children were randomly selected for this 
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study among participants with no reported malaria episodes 
defined by observation of P. falciparum parasites on blood smears, 
identified through passive case detection during 18  months of 
follow-up after third vaccination dose. Of note, PBMC samples 
from children who had malaria cases were reserved for future 
correlates analyses to test the selected markers identified in this 
study. Samples were collected in two different African centers: 
Manhiça Health Research Center, Fundação Manhiça (FM-CISM, 
Mozambique; 120 children), and Ifakara Health Institute and 
Bagamoyo Research and Training Centre (IHI-BRTC, Tanzania; 
59 children). The two sites had low-medium malaria transmission 
intensity at the time of the study (2–4). Investigators conducted 
all assays blinded to vaccination status.
sample collection
Blood was collected in 5  ml sodium citrate (BD Vacutainer® 
CPT™) tubes. PBMCs were isolated by density gradient cen-
trifugation, cryopreserved and shipped to the Fred Hutchinson 
Cancer Research Center where the PBMC were thawed and 
stained (see Methods in Supplementary Material).
PBMc stimulations
Thawed PBMC were rested in a 37°C, 5% CO2 incubator over-
night. The resting step increases the sensitivity of the assay (data 
not shown), probably by decreasing the stress and activation 
of PBMC due to the thawing process and exposure to the toxic 
cryopreservation agent. PBMC were stimulated with peptide 
pools covering the HBsAg or the CSP antigen present in the 
RTS,S vaccine (Table S1 in Supplementary Material). Negative 
controls contained 0.5% DMSO, the diluent for peptide pools, 
and Staphylococcal enterotoxin B was used as positive control 
stimulation at 1 µg/ml. Cultures were incubated 6 h at 37°C, 5% 
CO2. This short incubation time increases the sensitivity and 
specificity of the assay to detect antigen-specific cells, avoiding 
non-specific and secondary immune responses. Further details 
are found in Supplementary Material.
intracellular cytokine staining
Peripheral blood mononuclear cells were stained with one 
of two 16-color ICS panels that were designed for the study 
and that had previously undergone assay qualification with a 
formerly validated panel (17, 18). Cell staining was performed 
as described (17) (Supplementary Material). Antibody details 
can be found in Tables S2 and S3 in Supplementary Material. 
Data were acquired using a BD LSR II flow cytometer (BD 
Biosciences) directly from the plates using a high throughput 
sampler. We found some toxicity of HBsAg peptides, but since 
we could exclude dead cells, data were considered acceptable 
for analysis. We noted some spillover from CD154 to CXCR5 
and therefore, TFH-like cells were excluded from the analysis. 
Flow cytometry analysis was performed using FlowJo software 
(Version 9.9 Tree Star). Gating strategies for both panels are 
shown in Figures S1 and S2 in Supplementary Material.
statistical analysis
The raw FCS files and manual gates were imported into the R 
environment (19) using the OpenCyto framework (20) and cell 
counts for the cell gates of interest were obtained for all stimula-
tions and subjects.
For the analysis of the effect of vaccination on the frequen-
cies of cells expressing the functional markers, a multivariate 
linear mixed effect model was fitted using logarithm-10 trans-
formed cell frequencies (cells expressing the functional marker/
total number of cells within each cell subset) as an outcome. 
These models are commonly used (21–24) and allow to model 
jointly the different cell stimulations that each subject sample 
underwent using random effects. The model included a random 
intercept for the subject effect nested within stimulation and a 
random slope for timepoint. In these models, observations gen-
erated by different subjects (biological replicates) are assumed 
to be independent. We included the following predictors in the 
regression models (as fixed effects): stimulation (CSP, DMSO, 
or HBsAg and DMSO, as appropriate), time of visit (pre- vs. 
post-vaccination), and vaccination status (RTS,S/AS01E vs. 
comparator vaccine), as well as all interactions between the 
three factors to allow variations of responses across subgroups 
of vaccinees and time. Linear combination of coefficients 
in these models allowed addressing specific study questions 
(details in Supplementary Material). Through these models, we 
estimated the % change in cell frequencies in RTS,S/AS01E vs. 
comparator vaccinees at each timepoint, the % change from M0 
to M3 in each vaccine group, and the % change in RTS,S/AS01E 
vs. comparator vaccinees accounting for both timepoints. 
Statistical significance of comparisons was based on likelihood 
ratio tests. Antigen-specific responses were analyzed account-
ing for background, i.e., DMSO stimulation.
To define positivity of responses in each cell subset and sub-
ject, we identified the functional markers that were differentially 
expressed between the antigen (CSP or HBsAg) stimulations 
and their corresponding background (DMSO control stimula-
tion) for each cell subset, subject, and at each timepoint. Thus, 
the proportion of cells expressing that marker was compared 
between the two stimulation conditions for each subject and 
timepoint. The statistical method used was mixture models for 
single-cell assays (MIMOSA) (25), using the default algorithm 
(Expectation–Maximization algorithm) and a false-discovery 
rate of 0.05%. This method was chosen because it has higher 
sensitivity and specificity than alternative methods such as 
Fisher’s exact test (25). A separate model for each functional 
marker, cell subset, and stimulation was fitted. Once we had 
defined the positivity or negativity for each functional marker, 
cell subset, subject, and timepoint, then the proportion of chil-
dren with positive responses between vaccine groups at baseline 
or 1-month post-vaccination was compared using two-sided 
Fisher’s exact test.
Polyfunctional responses (cell subsets that express multiple 
functional markers) were analyzed using combinatorial polyfunc-
tionality analysis of antigen-specific T cell subsets (COMPASS) 
(26). COMPASS models all cell subsets expressing functional 
markers simultaneously and selects the subsets most likely to 
have a positive antigen-specific response. The antigen-specific 
response is quantified by the probability of having a positive 
response. COMPASS functionality and polyfunctionality scores, 
summarizing each subject’s polyfunctional profile, were compared 
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between vaccine groups using Wilcoxon test. The functionality 
score is the estimated proportion of antigen-specific cell subsets 
detected among all possible ones, whereas the polyfunctionality 
score is similar but weighted by the degree of polyfunctionality. 
In addition, COMPASS generates heatmaps that show the poste-
rior probabilities for each modeled cell subset for each subject. 
CD107a marker was eliminated from MIMOSA and COMPASS 
analysis, because peptide pool stimulation was associated with a 
FigUre 1 | Continued
FigUre 1 | Continued  
CSP- and hepatitis B surface antigen (HBsAg)-specific CD4+ T cell responses induced by RTS,S/AS01E. CSP- (a) and HBsAg- (B) specific CD4+ T cells expressing 
the common functional markers of both intracellular cytokine staining panels. (i) Forest plot showing the overall effect of RTS,S/AS01E (R) vaccination from baseline 
(M0) to 1 month post-third immunization (M3) taking into account the M0–M3 changes in comparator (C) vaccinees. The % change between RTS,S/AS01E and 
comparator vaccinees taking into account M0–M3 changes and 95% confidence intervals shown were obtained with a multivariate linear mixed effect model. P 
values (P) were obtained through likelihood ratio test and were adjusted for multiple testing (P-Adj) through Holm’s approach. (ii) Box plots showing the frequencies 
of CD4+ T cells expressing the functional markers after background subtraction found to be statistically significant in (i). Boxplots illustrate the medians and the 25th 
and 75th quartiles, and whiskers display 1.5 times interquartile ranges, outliers are not shown to facilitate visualization of the differences between comparison 
groups. Differences between vaccine groups at M0 and at M3 and differences from M0 to M3 within each vaccine group were computed through a multivariate 
linear mixed effect model and P values obtained through likelihood ratio test and were adjusted for multiple testing through Holm approach. Only significant P values 
adjusted for multiple testing are shown. Sample size in (a), for markers detected by both staining panels N = 100 RTS,S/AS01E and 65 comparator at M0, 100 
RTS,S/AS01E and 70 comparator at M3. For comparisons including M0 and M3, only subjects that had samples at both timepoints are included (N = 156 for 
markers detected by both panels, N = 83 for markers detected by panel 1, N = 73 for markers detected by panel 2). Sample size in (B) N = 62 RTS,S/AS01E and 
36 comparator at M0, 67 RTS,S/AS01E and 50 comparator at M3. For IL-17 (detected by panel 2) N = 30 RTS,S/AS01E and 18 comparator at M0, 37 RTS,S/
AS01E and 27 comparator at M3. For comparisons including M0 and M3, only subjects that had samples at both timepoints are included (N = 71 for markers 
detected by both panels, N = 35 for markers detected by panel 1, N = 36 for markers detected by panel 2).
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non-specific increase in CD107a compared to background, and 
response positivity could not be defined.
Statistical tests were considered significant at 0.05 α-level. 
Adjustments for multiple testing were done using Holm (27) 
and Benjamini–Hochberg (28) approaches. All analyses were 
conducted using R software. See Supplementary Material for 
detailed descriptions.
resUlTs
study Population
We used two different multiparameter ICS panels to assess cellu-
lar immune responses specific to the RTS,S/AS01E vaccine anti-
gens. PBMC from 55 RTS,S and 41 comparator vaccinees, and 50 
RTS,S and 33 comparator vaccinees were stained with antibody 
panel 1 (P1) and panel 2 (P2), respectively. The two panels had 
the same set of core markers, which allowed the exclusion of 
dead cells, monocytes (CD14), identification of CD4+ and CD8+ 
T cells (CD4, CD8 and CD3), NK and NK-T cells (CD56), the 
TH1 cytokines IFN-γ, IL-2, and TNF-α, the TH2 cytokine IL-4, 
the costimulatory molecule CD154 (CD40L), and the cytotoxic 
marker granzyme B (Figures S1 and S2 in Supplementary 
Material; Tables S2 and S3 in Supplementary Material). P1 
additionally had CD45RA and CCR7 markers that allowed the 
identification of memory cell subsets, and IL-21, a cytokine 
related to TFH. Panel 2 (P2) included γδ TCR for the identifica-
tion of γδ T cells and several functional markers: the regulatory 
cytokine IL-10, the TH2 cytokine IL-13, the TH17 cytokine IL-17, 
and cytotoxicity marker CD107a. The gating strategy is detailed 
in Figures S1 and S2 in Supplementary Material. The common 
set of core markers (lineage and functional markers) allowed 
the pooled analysis for these markers. Males and females were 
similarly represented in both study sites and vaccine groups, 
with a proportion of 59 and 56.8% females in the RTS,S/AS01E 
and comparator groups, respectively.
Frequencies of csP- and hBsag-specific 
cD4+ T cells induced by rTs,s/as01e
We compared frequencies of CSP- or HBsAg-specific T  cells 
expressing functional markers in RTS,S- and rabies-vaccinated 
children, accounting for the pre-vaccination frequencies in a 
multivariate model. RTS,S/AS01E-vaccinated children had a 
statistically significant increase of CSP-specific CD4+ T  cells 
expressing IL-2 (217% increase), TNF-α (72.3%), and CD154 
(101.4%) from baseline to post-vaccination in contrast to the 
rabies vaccinees (Figure 1A, i). We observed larger increases over 
time of HBsAg-specific CD4+ T cells expressing IL-2 (732.2%), 
TNF-α (346%), and CD154 (268.3%) (Figure  1B, i) in RTS,S/
AS01E than in rabies vaccinees.
Figure  1A (ii) and Figure  1B (ii) show the frequencies 
of CSP- and HBsAg-specific CD4+ T  cells after background 
subtraction. Higher frequencies of CSP- and HBsAg-specific 
CD4+ T  cells expressing the above markers, and additionally 
HBsAg-specific CD4+ T cells expressing IFN-γ and IL-17 cells, 
were observed in RTS,S/AS01E vaccinees at post-vaccination 
compared to baseline and to comparators. No differences were 
detected between the two vaccine groups at baseline, or from 
baseline to post-vaccination in comparator vaccinees, the latter 
suggesting that there was no effect of naturally acquired immu-
nity on cellular responses.
Antigen-specific T  cells in memory subsets, defined by 
CD45RA and CCR7, were analyzed following vaccination. CD4+ 
TCM (CD45RA− CCR7+) and CD4+ TEM (CD45RA− CCR7−) cells 
recognized both vaccine antigens. After accounting for baseline 
frequencies, RTS,S/AS01E vaccinees had more CSP-specific 
CD4+ TEM cells producing IL-2 and TNF-α, respectively, than 
comparator vaccinees (Figure  2A, i). Comparisons between 
vaccine groups at post-vaccination and from baseline to post-
vaccination revealed additional responses: higher frequencies 
of CD4+ TCM expressing IL-2 and TNF-α and CD4+ TEM cells 
expressing CD154, IL-4 and IL-21, in RTS,S/AS01E than com-
parator vaccinees (Figure  2A, ii). Regarding HBsAg-specific 
responses, RTS,S/AS01E vaccinees had increased frequencies 
of CD4+ TCM producing IL-2, TNF-α and CD154 and CD4+ TEM 
producing IL-2, TNF-α, CD154 and IL-21 than comparator 
vaccinees (Figure 2B, i).
Therefore, RTS,S/AS01E vaccination induced CSP and 
HBsAg-specific CD4+ TCM and CD4+ TEM with TH1, and addi-
tional TH2, and TFH functions. No overall effect of RTS,S vaccina-
tion was detected on the frequencies of terminally differentiated 
CD4+ T cells (CD45RA+ CCR7−), naïve CD4+ T cells (CD45RA+ 
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FigUre 2 | Continued
FigUre 2 | Continued  
CSP- and hepatitis B surface antigen (HBsAg)-specific CD4+ T cell memory responses induced by RTS,S/AS01E. CSP- (a) and HBsAg- (B) specific memory CD4+ 
T cell subsets [central memory (CM); effector memory (EM); naive (N); terminally differentiated (TD)] expressing functional markers measured in the intracellular 
cytokine staining panels panel 1. (i) Forest plot showing the overall effect of RTS,S/AS01E (R) vaccination from baseline (M0) to 1 month post-third immunization 
(M3) taking into account the M0–M3 changes in comparator (C) vaccinees. The % change between RTS,S/AS01E and comparator vaccinees and 95% confidence 
intervals shown were obtained with a multivariate linear mixed effect model. P values (P) were obtained through likelihood ratio test and were adjusted for multiple 
testing (P-Adj) through Benjamini–Hochberg approach. (ii) Box plots showing the frequencies of CD4+ TCM and CD4+ TEM cells expressing selected functional markers 
after background subtraction. Boxplots illustrate the medians and the 25th and 75th quartiles, and whiskers display 1.5 times interquartile ranges, outliers are not 
shown to facilitate visualization of the differences between comparison groups. Differences between vaccine groups at M0 and at M3 and differences from M0 to M3 
within each vaccine group were computed through a multivariate linear mixed effect model and P values obtained through likelihood ratio test and were adjusted for 
multiple testing through Holm approach. Only significant P values adjusted for multiple testing are shown. Sample size in (a) For N = 53 RTS,S/AS01E and 35 
comparator at M0, 52 RTS,S/AS01E and 39 comparator at M3. For comparisons including M0 and M3, only subjects that had samples at both timepoints are 
included (N = 83). Sample size in (B) N = 32 RTS,S/AS01E and 18 comparator at M0, 37 RTS,S/AS01E and 27 comparator at M3. For comparisons including M0 
and M3, only subjects that had samples at both timepoints are included (N = 35).
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CCR7+), other analyzed cell subsets (NK, NK-T like, γδ T, CD8+ 
T  cells) or on other functional markers (Tables S5 and S6 in 
Supplementary Material).
non-specific cD4+ T cell and cD8+ T cell 
responses induced by rTs,s/as01e 
Vaccination
Analysis of frequencies of cell subsets expressing functional 
markers in the background (DMSO, serving as the unstimu-
lated control) revealed non-specific responses (i.e., not specific 
for CSP or HBsAg) upon RTS,S/AS01E vaccination (Figure 3). 
Accounting for baseline and responses in comparator vac-
cinees, RTS,S/AS01E vaccination increased the frequencies of 
CD4+ T  cells producing IL-2 or TNF-α or CD154, IL-4, and 
CD107a (Figure  3A, i). In comparator vaccinees, a decrease 
in these two subsets from baseline to post-vaccination was 
detected. Interestingly, RTS,S/AS01E vaccination also increased 
the frequencies of CD8+ T  cells producing IL-4 and CD107a 
(Figure 3B, i).
Since we detected an effect of RTS,S/AS01E vaccination in 
the background, we looked at the ex vivo antigen stimulations 
when not accounting for background. RTS,S/AS01E-vaccinated 
children had CD4+ T  cells and CD8+ T  cells expressing IL-4 
and CD107a, as was observed for the background alone and, 
thus, likely reflecting non-specific responses (Figure S3 in 
Supplementary Material). Additionally, RTS,S/AS01E vaccina-
tion increased the frequencies of CD4+ T cells expressing IL-13 
and CD8+ T  cells expressing CD154 and IL-2 or TNF-α or 
CD154 following CSP stimulation when not taking background 
into account (Figure S3 in Supplementary Material). These addi-
tional responses in RTS,S/AS01E-vaccinated children were no 
longer significant when taking into account the background and 
likely reflect a non-specific effect of RTS,S/AS01E vaccination.
higher Proportion of Positive cD4+ T cell 
responses Defined by MiMOsa in  
rTs,s/as01e than comparators
To assess the vaccine specificity of the antigen-specific T cell 
responses detected and the rate of responders to the RTS,S/
AS01E vaccine (participants whose T-cells responded to 
stimulation), we determined the positivity of the responses for 
each subject comparing the frequencies of T cells expressing a 
functional marker in the antigen-stimulated and unstimulated 
control conditions for each participant using the MIMOSA 
statistical method. If a response is truly vaccine specific, one 
would expect to detect it after vaccination but not at baseline 
or in the comparator vaccinees. We found a significantly higher 
proportion of IL-2+, TNF-α+, and CD154+ CD4+ T cell positive 
CSP-specific responses in RTS,S/AS01E than in comparator 
vaccinees post-vaccination (Table 1). Response rates for these 
markers ranged from 24 to 30% in RTS,S/AS01E vaccinees; 
whereas for comparator vaccinees, there were none or very few 
responses (Table 1). Similarly, CSP-specific positive responses 
were absent or very low at baseline, supporting the specific-
ity of the definition of positivity (Table S7 in Supplementary 
Material).
For HBsAg, we additionally detected more IFN-γ+ and IL-17+ 
CD4+ T cell positive responses in RTS,S/AS01E than comparator 
vaccinees at post-vaccination. Rates of HBsAg responders ranged 
from 26.7 to 76.1% in RTS,S/AS01E vaccinees (Table 1). However, 
a proportion of comparator vaccinees at post-vaccination and 
all vaccinees at M0 were also positive (Table  1; Table S7 in 
Supplementary Material), likely due to the fact that these children 
received the hepatitis B vaccine during the Expanded Program of 
Immunization (EPI) before the study. Most of the CSP respond-
ers were also HBsAg responders (Figure S4 in Supplementary 
Material).
When looking at CD4+ TCM and CD4+ TEM cell subsets, 
we found a significantly higher proportion of CSP respond-
ers in RTS,S/AS01E than in comparator vaccinees for IL-2, 
TNF-α, and CD154 (Table  2). Regarding HBsAg responses, 
RTS,S/AS01E vaccinees had higher rates of IL-2 and CD154 
responses in CD4+ TCM cells and IFN-γ, IL-2, TNF-α, 
CD154 and IL-21 responses in CD4+ TEM than comparator 
vaccinees. Very few positive responses to CSP and HBsAg 
were detected in comparator vaccinees or at baseline 
(Table  2; Table S8 in Supplementary Material). Almost 
no positive responses were found in the other cell subsets 
analyzed (CD4+ TTD, CD4+ TN, NK, NK-T like, γδ T, CD8+ T cells, 
and memory CD8+ T cell subsets), and no significant differences 
were detected between vaccination groups for any of the two 
vaccine antigens (Tables S9–S11 in Supplementary Material).
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csP- and hBsag-specific Polyfunctional 
cD4+ T cell responses induced by  
rTs,s/as01e
When analyzing the pooled data for the functional markers 
included in both panels, RTS,S/AS01 vaccinees had significantly 
higher functionality and polyfunctionality scores for CSP- and 
HBsAg-specific CD4+ T  cells than comparator vaccinees 
(Figures 4A,B). Heatmaps of posterior probabilities of responses 
showed CSP-specific CD4+ T  cell responses among subsets 
coexpressing three markers (IL-2, TNF-α, and CD154), and 
two markers (TNF-α and CD154; IL-2 and TNF-α) in RTS,S/
FigUre 3 | Continued
FigUre 3 | Continued  
Non-specific CD4+ T and CD8+ T cell responses induced by RTS,S/AS01E as determined by the difference between M0 and M3 for the control stimulation. 
Frequencies in control stimulations (stimulation with the peptide diluent, DMSO, considered background) of CD4+ T cells (a) and CD8+ T cells (B) expressing the 
common functional markers of both intracellular cytokine staining panels and also functional markers measured separately in each panel. (i) Forest plot showing the 
overall effect of RTS,S/AS01E (R) vaccination from baseline (M0) to 1 month post-third immunization (M3) taking into account the M0–M3 changes in comparator (C) 
vaccinees. The % change between RTS,S/AS01E and comparator vaccinees and 95% confidence intervals shown were obtained with a multivariate linear mixed 
effect model. P values (P) were obtained through likelihood ratio test and were adjusted for multiple testing (P-Adj) through Holm approach. (ii) Box plots showing the 
frequencies of T cells expressing functional markers when significant differences were detected. Boxplots illustrate the medians and the 25th and 75th quartiles, and 
whiskers display 1.5 times interquartile ranges, outliers are not shown to facilitate visualization of the differences between comparison groups. Differences between 
vaccine groups at M0 and at M3 and differences from M0 to M3 within each vaccine group were computed through a multivariate linear mixed effect model and P 
values obtained through likelihood ratio test and were adjusted for multiple testing through Holm approach. Only significant P values adjusted for multiple testing are 
shown. Sample size in (a) for markers detected by both staining panels N = 100 RTS,S/AS01E and 65 comparator at M0, 101 RTS,S/AS01E and 70 comparator at 
M3. For CD107a (detected by panel 2), N = 47 RTS,S/AS01E and 30 comparator at M0, 49 RTS,S/AS01E and 31 comparator at M3. For comparisons, including 
M0 and M3, only subjects that had samples at both timepoints are included (N = 157 for markers detected by both panels, N = 83 for markers detected by panel 1 
and N = 74 for markers detected by panel 2). Sample size in (B) for markers common from both staining panels N = 100 RTS,S/AS01E and 64 comparator at M0, 
99 RTS,S/AS01E and 69 comparator at M3. For CD107a N = 47 RTS,S/AS01E and 30 comparator at M0, 47 RTS,S/AS01E and 31 comparator at M3. For 
comparisons including M0 and M3, only subjects that had samples at both timepoints are included (N = 154 for markers detected by both panels, N = 82 for 
markers detected by panel 1 and N = 742 for markers detected by panel 2).
TaBle 1 | Comparison of proportion of positive CD4+ T cell responses to CSP and hepatitis B surface antigen (HBsAg) between RTS,S/AS01E and comparator 
vaccinees 1-month post-third vaccination.
csP hBsag
rTs,s/as01e comparator P-value rTs,s/as01e comparator P-value
Functional 
markera
intracellular 
cytokine staining 
panelb
Positive/total (%) Positive/total (%) raw Pc adj Pd Positive/total (%) Positive/total (%) raw Pc adj Pd
IFN-γ P1 and P2 1/100 (1%) 0/70 (0%) 1 1 34/67 (50.75%) 9/50 (18%) <0.001 0.001
IL-2 P1 and P2 30/100 (30%) 0/70 (0%) <0.001 <0.001 49/67 (73.13%) 9/50 (18%) <0.001 <0.001
TNF-α P1 and P2 24/100 (24%) 0/70 (0%) <0.001 <0.001 48/67 (71.64%) 4/50 (8%) <0.001 <0.001
CD154 P1 and P2 29/100 (29%) 5/70 (7.14%) <0.001 0.002 51/67 (76.12%) 15/50 (30%) <0.001 <0.001
IL-4 P1 and P2 0/100 (0%) 2/70 (2.86%) 0.17 0.5 17/67 (25.37%) 6/50 (12%) 0.1 0.2
IL-2 or TNF-α or 
CD154
P1 and P2 21/100 (21%) 0/70 (0%) <0.001 <0.001 46/67 (68.66%) 2/50 (4%) <0.001 <0.001
IL-21 P1 2/52 (3.85%) 0/39 (0%) 0.5 1 20/37 (54.05%) 12/27 (44.44%) 0.61 1
IL-10 P2 0/48 (0%) 0/31 (0%) 1 1 3/30 (10%) 2/23 (8.7%) 1 1
IL-13 P2 5/48 (10.42%) 1/31 (3.23%) 0.39 1 20/30 (66.67%) 8/23 (34.78%) 0.03 0.11
IL-17 P2 1/48 (2.08%) 0/31 (0%) 1 1 8/30 (26.67%) 0/23 (0%) 0.007 0.03
Bold font indicates differences with p-values <0.05.
aGranzyme B was included in the analysis, but not shown because it is constitutively expressed independently of cell stimulation and activation.
bData from markers detected by both staining panels, P1 and P2, are combined.
cRaw P, original P-value computed based on two-sided Fisher’s exact test.
dAdj P, P values adjusted for multiple testing through Holm’s approach.
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AS01E vaccinees, whereas almost no responses were detected in 
comparator vaccinees or at baseline (Figure 4A, ii). For HBsAg 
responses, more CD4+ T cell subsets with positive responses and 
with higher degree of polyfunctionality were detected in RTS,S/
AS01E vaccinees (Figure  4B, ii). Besides the same triple- and 
double-positive CD4+ T cell responses recognizing CSP antigen, 
we also detected CD154+ IL-2+ TNF-α+ IFN-γ+ CD4+ T  cells 
and CD154+ IL-2+ TNF-α+ IL4+ CD4+ T cells. By contrast, com-
parator vaccinees or all vaccinees at baseline had none or weak 
responses in these subsets that could be explained by background 
responses to previous malaria exposure or hepatitis B vaccination. 
Therefore, RTS,S/AS01E induced polyfunctional CD4+ T cells to 
both vaccine antigens, with a higher degree of polyfunctionality 
for HBsAg that included TH1 and TH2 responses.
When the COMPASS analysis was performed using all the 
functional makers included in each antibody panel separately, we 
identified additional highly polyfunctional CD4+ T cell subsets 
coexpressing IL-13 (for both vaccine antigens) or IL-21 (for 
HBsAg) in addition to IL-2, TNF-α and CD154 (Figure S5 in 
Supplementary Material). This further highlights the induction 
of highly polyfunctional CD4+ T cell subsets with a TH2 and TFH 
functions by RTS,S/AS01E. No polyfunctional responses were 
detected in CD8+ T cells for either vaccine antigen.
DiscUssiOn
We provide a detailed characterization of the ex vivo antigen-
specific T cell response induced by RTS,S/AS01E vaccination in a 
pediatric Phase III trial (2–4). In addition to previously described 
IL-2- and TNF-α-expressing CD4+ T cell responses (5–10), we 
have identified for the first time in a pediatric field trial TH2 
effector functions and IL-21 in RTS,S vaccinees, attributed the 
responses to the central memory (CM) and effector memory 
(EM) compartments, and observed polyfunctional CD4+ T cell 
TaBle 2 | Comparison of proportion of positive responses to CSP and hepatitis B surface antigen (HBsAg) in memory CD4+ T cell subsets between RTS,S/AS01E and 
comparator vaccinees 1-month post-third vaccination.
csP hBsag
rTs,s/as01e comparator P-value rTs,s/as01e comparator P-value
Memory subset Functional 
markera
Positive/total (%) Positive/total (%) raw Pb adj Pc Positive/total (%) Positive/total (%) raw Pb adj Pc
CM IFN-γ 1/52 (1.92%) 0/39 (0%) 1 1 1/37 (2.7%) 0/27 (0%) 1 1
IL-2 12/52 (23.08%) 0/39 (0%) <0.001 0.009 14/37 (37.84%) 0/27 (0%) <0.001 0.001
TNF-α 8/52 (15.38%) 0/39 (0%) 0.01 0.049 8/37 (21.62%) 0/27 (0%) 0.02 0.058
CD154 11/52 (21.15%) 0/39 (0%) 0.002 0.01 12/37 (32.43%) 1/27 (3.7%) 0.005 0.02
IL-4 0/52 (0%) 0/39 (0%) 1 1 2/37 (5.41%) 0/27 (0%) 0.5 1
IL-21 0/52 (0%) 0/39 (0%) 1 1 0/37 (0%) 0/27 (0%) 1 1
EM IFN-γ 1/52 (1.92%) 0/39 (0%) 1 1 9/37 (24.32%) 0/27 (0%) 0.008 0.03
IL-2 21/52 (40.38%) 0/39 (0%) <0.001 <0.001 23/37 (62.16%) 1/27 (3.7%) <0.001 <0.001
TNF-α 12/52 (23.08%) 0/39 (0%) <0.001 0.009 18/37 (48.65%) 0/27 (0%) <0.001 <0.001
CD154 14/52 (26.92%) 2/39 (5.13%) 0.01 0.049 21/37 (56.76%) 1/27 (3.7%) <0.001 <0.001
IL-4 4/52 (7.69%) 0/39 (0%) 0.13 0.46 8/37 (21.62%) 1/27 (3.7%) 0.07 0.19
IL-21 7/52 (13.46%) 0/39 (0%) 0.02 0.07 16/37 (43.24%) 2/27 (7.41%) 0.002 0.01
TD IFN-γ 0/52 (0%) 0/39 (0%) 1 1 0/37 (0%) 0/27 (0%) 1 1
IL-2 0/52 (0%) 0/39 (0%) 1 1 0/37 (0%) 0/27 (0%) 1 1
TNF-α 0/52 (0%) 0/39 (0%) 1 1 0/37 (0%) 0/27 (0%) 1 1
CD154 0/52 (0%) 0/39 (0%) 1 1 0/37 (0%) 0/27 (0%) 1 1
IL-4 0/52 (0%) 0/39 (0%) 1 1 0/37 (0%) 0/27 (0%) 1 1
IL-21 0/52 (0%) 0/39 (0%) 1 1 0/37 (0%) 0/27 (0%) 1 1
Naive IFN-γ 0/52 (0%) 0/39 (0%) 1 1 1/37 (2.7%) 2/27 (7.41%) 0.57 1
IL-2 0/52 (0%) 0/39 (0%) 1 1 4/37 (10.81%) 2/27 (7.41%) 1 1
TNF-α 0/52 (0%) 0/39 (0%) 1 1 5/37 (13.51%) 0/27 (0%) 0.07 0.19
CD154 0/52 (0%) 0/39 (0%) 1 1 1/37 (2.7%) 0/27 (0%) 1 1
IL-4 0/52 (0%) 0/39 (0%) 1 1 0/37 (0%) 0/27 (0%) 1 1
IL-21 0/52 (0%) 0/39 (0%) 1 1 14/37 (37.84%) 11/27 (40.74%) 1 1
Bold font indicates differences with p-values <0.05.
CM, central memory (CD45RA− CCR7+); EM, effector memory (CD45RA− CCR7−); TD, terminally differentiated (CD45RA+ CCR7−).
aGranzyme B was included in the analysis, but not shown because it is constitutively expressed independently of cell stimulation and activation.
bRaw P, original P-value computed based on two-sided Fisher’s exact test.
cAdj P, P values adjusted for multiple testing through Benjamini–Hochberg approach.
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responses, which may be a key feature of a protective response. 
Although this analysis was limited to vaccine recipients who did 
not become infected with P. falciparum, this study has identified 
key immune responses that can be examined in a larger case-
control study within this trial.
RTS,S/AS01E vaccination induced distinct antigen-specific 
CD4+ T  cell populations in a subset of children: CSP-specific 
IL-2, TNF-α, and CD154 CD4+ T  cell responses and HBsAg-
specific IFN-γ, IL-2, TNF-α, CD154, and IL-17 CD4+ T  cell 
responses. Frequencies of cytokine-positive CD4+ T  cells 
were consistent with the frequencies of IL-2 and TNF-α CSP-
specific responses reported previously in RTS,S Phase II trials 
in endemic areas (5–10). Although no clear associations of 
TNF-α and IL-2 responses with protection were found in past 
field studies, they could contribute in RTS,S-induced protection 
(8, 9). TNF-α is an effector cytokine that may mediate mecha-
nisms of P. falciparum pre-erythrocytic protection (29–31) 
and IL-2 induces proliferation of T  cells and amplifies effector 
functions. CD4+ T  cells producing IL-2 may contribute to the 
memory pool of CD4+ T cells with effector functions since they 
can be maintained during long periods of time and can develop 
into IFN-γ-producing T cells following subsequent stimulation 
(32). Of note, rates of IL-2 CSP responders (23–40% depending 
on the CD4+ T cell subset) were similar to the estimated VE in 
the Phase III trial (50% after a year of follow-up or 28% till study 
end) (4). IL-2 expression can also induce NK activation and 
secretion of IFN-γ (10, 33, 34), a key effector cytokine involved 
in malaria protection (35). Contrary to previous findings, we 
did not detect IFN-γ expression in CD4+ T  cells or NK  cells 
ex vivo following CSP stimulation (5, 7, 8, 10, 14). This is probably 
due to the short stimulation time in our study compared to longer 
times in whole blood assays from previous studies, which allowed 
bystander activation of CD4+ T cells and NK cells through IL-2 
(10). Remarkably, we detected CD40L expression in antigen-
specific CD4+ T cells, in contrast to previous field studies (6, 7).
Importantly, CD4+ T cell responses were detected in CM and 
EM compartments. Memory phenotypes are relevant to define 
high-quality and long-lasting responses, for instance, the higher 
proliferative potential of CM cells has been associated with pro-
tection from infection (32, 36–38). CD4+ TCM responses could, 
therefore, be involved in long-lasting protection, whereas the 
CD4+ TEM responses could be associated with the short protec-
tion observed in the trial. IL2+, CD154+, and TNF-α+ CD4+ 
TCM cells were detected, whereas CD4+ TEM cells had additional 
effector functions, in accordance with the different cytokine 
profiles associated with these memory T cell subsets (32, 39, 40) 
FigUre 4 | CSP- (a) and hepatitis B surface antigen (HBsAg)-specific (B) CD4+ T cell polyfunctional responses. (i) Box plots of functionality and polyfunctionality 
scores calculated by combinatorial polyfunctionality analysis of antigen-specific T cell subsets (COMPASS), stratified by vaccine group and timepoint. The 
functionality score represents the estimated proportion of cell subsets showing positive responses among all possible cell subsets expressing any functional marker, 
whereas the polyfunctional score is similar but it is weighted by the degree of polyfunctionality. Boxplots illustrate the medians and the 25th and 75th quartiles, and 
whiskers display 1.5 times interquartile ranges. COMPASS analysis was performed using the common markers of both panels and all subjects with data (IL-4, IFN-γ, 
granzyme B (GzB), IL-2, TNF-α, CD154, 64 possible subsets). P values computed through Wilcoxon tests and adjusted for multiple testing through Holm approach 
separately for CSP and HBsAg antigens are shown. (ii) Heatmap of COMPASS posterior probabilities showing CD4+ T cell responses to CSP and HBsAg in RTS,S/
AS01E and comparator vaccinees at pre-vaccination (M0) and 1 month post-third vaccination (M3). Columns represent functional cell subsets with detectable 
antigen-specific responses, color coded by the number of functional markers they express and are ordered by increasing degree of polyfunctionality. Rows represent 
study children, which are stratified by vaccine status, at the top the comparator vaccinees and at the bottom the RTS,S/AS01E vaccinees. Each cell shows the 
probability (color coded by purple intensity) that the corresponding child shows an antigen-specific response in the corresponding cell subset. Sample size in (a) 
N = 100 RTS,S/AS01E and 65 comparator at M0, 100 RTS,S/AS01E and 70 comparator at M3; (B) N = 62 RTS,S/AS01E and 36 comparator at M0, 67 RTS,S/
AS01E and 50 comparator at M3.
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and studies reporting CD4+ TEM cells as the main producers of 
effector cytokines (32, 40). Higher frequencies of CD4+ TEM cells 
expressing IL-4, and IL-21 for both vaccine antigens, and IFN-γ 
for HBsAg, were detected in RTS,S/AS01E-vaccinated children 
compared to baseline frequencies or comparator vaccinees. TH2 
(IL-4) and TFH (IL-21) effector functions together with CD40L 
could provide help to B  cells for humoral responses and may 
correlate with antibody responses (41–44). No responses were 
detected in CD4+ TTD cells, a cell subset with high IFN-γ effec-
tor function, with no long-term memory potential and fated for 
death (32).
RTS,S/AS01E vaccination induced polyfunctional CSP- and 
HBsAg-specific CD4+ T cells. This finding is particularly impor-
tant since multifunctional T cells have been associated with higher 
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quality responses and risk (26) or protection from infections 
(45, 46). Most CSP and HBsAg positive responses were found 
in the triple functional marker CD4+ T cell subset coexpressing 
IL-2, TNF-α, and CD154, although we also observed responses 
in a 4-function subset coexpressing IL-13. For HBsAg, we also 
found numerous responses in CD4+ T  cells subsets simultane-
ously producing four functional markers: IL-2, TNF-α, CD154 
plus IL-21 or IFN-γ or IL-4, reflecting TFH, TH1 and TH2 distinct 
differentiation of these effector cell subsets.
Overall, HBsAg-specific responses were of higher magni-
tude, effector breadth and polyfunctionality than CSP-specific 
responses, suggesting a higher quality of response probably due 
to a booster effect since children should have been previously vac-
cinated with hepatitis B, or a higher immunogenicity of HBsAg 
compared to CSP due to the higher proportion of HBsAg than 
CSP in RTS,S (4:1).
RTS,S/AS01E may have a non-specific effect since higher 
background CD4+ T  cell and CD8+ T  cell responses were 
detected after vaccination compared with baseline. Since these 
responses included IL-4 and CD107a, it could be indicating a 
bias to a TH2 status and higher cytolytic potential of T cells in 
RTS,S/AS01E-vaccinated children. There is increasing evidence 
of non-specific effect of vaccines (47, 48), but a non-specific effect 
of RTS,S/AS01E may still have an impact on the response against 
P. falciparum infection. The significance of these responses may 
be worth noting in the context of the future correlates analyses. 
This finding of a non-specific effect highlights the importance of 
correcting for the background (by subtracting background) in 
order to assess antigen-specific effects.
In this study, we only included children without experiencing 
a documented malaria episode during the 18  months of 
follow-up; therefore, the clinical relevance of our findings will 
be assessed in future correlates studies. The exclusion of malaria 
cases is unlikely to bias results and affect study conclusions since 
malaria transmission intensity was low at that time in Manhiça 
and Bagamoyo and lack of malaria is not likely to be due solely 
to vaccine-induced protection, but also to lack of exposure to 
the mosquito-bearing parasite. Another potential limitation of 
our study relates to the toxicity of HBsAg peptide concentration 
used. Although this could impact cellular responsiveness, we did 
exclude dead and dying cells in the analysis, and it is likely that 
any impact would affect both vaccine groups.
The breadth of functions, patterns, and variability of responses 
to CSP, together with memory phenotypes of responding cell 
subsets described in our study, reflects a complex response to the 
RTS,S/AS01 vaccine. These responses, together with anti-CSP 
IgG data, may provide insights into the lack of protection in a 
substantial proportion of vaccinees, and may be key in providing 
correlates for VE and duration of protection.
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